Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + SOX for Neoadjuvant Gastric Adenocarcinoma
NCT06192186Phase 4Recruiting
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of adebrelimab in gastric adenocarcinoma. Started Dec 2023; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT06192186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06192186.